The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCppgroup Regulatory News (CPP)

Share Price Information for Cppgroup (CPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 189.00
Bid: 175.00
Ask: 179.00
Change: -5.50 (-3.01%)
Spread: 4.00 (2.286%)
Open: 175.00
High: 189.00
Low: 175.00
Prev. Close: 182.50
CPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Globiva Divestment

27 Nov 2023 07:00

RNS Number : 6728U
CPPGroup Plc
27 November 2023
 

27 November 2023

CPPGroup Plc

("the Group"; or "the Company")

 

Globiva Divestment

 

CPP Group (AIM: CPP), a provider of real-time assistance products and resolution services which reduce disruptions to everyday life for millions of customers across the world, has entered into an agreement (the "Agreement") with the founders of Globiva Services Private Ltd ("Globiva") for the disposal of the Group's majority interest in Globiva for an aggregate consideration of approximately £5.1 million1 (the "Transaction"). Globiva is non-core to the Group following the announcement of its revised strategy and Change Management Programme ("CMP") in October 2022 to transform the Group to an InsurTech business, led by Blink Parametric ("Blink").

 

Background

The Group holds a 51% majority interest in Globiva, a Business Processes Management company incorporated in India, with the other 49% of the shares beneficially owned by the three founders of Globiva, Navneet Gupta, Vikram Singh Nathawat, and Ashish Goyal, who continue to manage the business (the "Globiva Founders").

 

Under amended arrangements entered into on 20 July 2022, the Globiva Founders had the option to buy back 10% of the ordinary shares in Globiva, from the Group, for a pre-agreed price of approximately £0.9 million. This was subject to Globiva meeting certain performance targets, which it is on track to achieve. However, in the normal course of business, it was further agreed that this could not be triggered until 1 January 2026 at the earliest. This Agreement supersedes the previous arrangements.

 

Transaction Rationale

· The Transaction is consistent with the Group's stated strategy to transform the Group to an InsurTech business led by Blink and supported by India and Turkey.

· The Group is currently a "trapped" investor in Globiva with limited options to realise value. In addition, the Group was likely to become a minority shareholder (January 2026) and consequently would have lost majority voting rights on key strategic decisions. The Transaction provides an exit path for the Group at an acceptable return.

· The Transaction provides cash flow, not previously forecast, over a three-year period to support the Group's CMP.

 

Transaction Structure

· The sale and transfer of ownership will be conducted over a three-year period concluding in Q1 2027.

· The total aggregate consideration of approximately £5.1 million1 (515 million Indian rupees) represents a blended 7.1x multiple on forecast EBITDA for the 2023, 2024 and 2025 calendar years. Final consideration will be based on audited EBITDA and subject to a maximum adjustment of plus or minus ten percent.

· The Group's shareholding in Globiva, currently 51%, will reduce to approximately 35% in Q1 2025; 13% in Q1 2026; and zero percent in Q1 2027.

· Cash, subject to any EBITDA performance adjustment (noted above) will be received by the Group as follows: approximately £1.2 million in 2024; £1.3 million in 2025; £1.2 million in 2026; and £1.4 million in 2027.

 

For the 2022 financial year, Globiva contributed EBITDA of £2.4 million to the Group's overall EBITDA from continuing operations of £6.9 million, albeit the Group's shareholders only ultimately benefit from 51% of Globiva's results. As at 30 June 2023, Globiva had net assets of £3.6 million.

The Transaction constitutes a related party transaction, pursuant to Rule 13 of the AIM Rules for Companies, as the Globiva Founders are Directors of Globiva. The Group's Directors consider, having consulted with the Company's nominated adviser, Liberum Capital Limited, that the terms of the Transaction are fair and reasonable insofar as the Company's shareholders are concerned.

 

Simon Pyper, Group CEO, commented:

"The agreement we have reached with Globiva is consistent with our stated strategy and provides a positive outcome for both parties. This is another forward step as we simplify the Group and transform to an InsurTech business."

 

1 Approximate, as subject to currency exchange movements.

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Enquiries:

 

CPP Group plc

Simon Pyper, Chief Executive Officer Tel: +44 (0)7917 795601

David Bowling, Chief Financial Officer

 

 

Liberum Capital Limited

(Nominated Adviser and Sole Broker) Tel: +44 (0)20 3100 2000

Richard Lindley

Lauren Kettle

 

About CPP Group:

CPP Group is a technology-driven assistance company that creates embedded and ancillary real-time assistance products and resolution services that reduce disruption to everyday life for millions of people across the world, at the time and place they are needed, CPP Group is listed on AIM, operated by the London Stock Exchange.

 

For more information on CPP visit https://corporate.cppgroup.com/

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBFBLTMTTTBLJ
Date   Source Headline
23rd Apr 20247:00 amRNSBlock listing Interim Review
3rd Apr 202410:29 amRNSPosting of Annual Report and Notice of AGM
26th Mar 20247:00 amRNSFULL YEAR RESULTS FOR YEAR ENDED 31 DECEMBER 2023
20th Mar 20242:12 pmRNSInvestor presentation via Investor Meet Company
15th Feb 20242:31 pmRNSDivestment of minority holding in KYND Limited
22nd Jan 20247:00 amRNSTrading Update for Financial Year 2023
11th Jan 20247:00 amRNSBlink progress in 2023
21st Dec 20237:00 amRNSBlock Listing of Ordinary Shares
20th Dec 20237:00 amRNSBlink Parametric signs Blue Cross extension
18th Dec 20237:00 amRNSBlock listing Interim Review and Cancellation
27th Nov 20237:00 amRNSGlobiva Divestment
2nd Nov 20237:00 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSBlink Parametric new client wins
25th Oct 20231:59 pmRNSBlock listing Interim Review
6th Oct 20237:00 amRNSBoard Update
2nd Oct 20237:00 amRNSResponse to press article
28th Sep 20233:03 pmRNSDirector/PDMR Shareholding
28th Sep 20237:00 amRNSAwards under Long Term Incentive Plan
19th Sep 20237:00 amRNSHalf-year Report for 6 months ended 30 June 2023
19th Sep 20237:00 amRNSStatement regarding change of website address
15th Sep 20237:00 amRNSInvestor presentation via Investor Meet Company
18th Jul 20237:00 amRNSTrading Update for six months ended 30 June 2023
26th Jun 20239:00 amRNSBlink Parametric new client wins
20th Jun 20237:00 amRNSBlock listing Interim Review
12th Jun 20237:00 amRNSHolding(s) in Company
9th Jun 20237:00 amRNSHolding(s) in Company
6th Jun 20239:34 amRNSHolding(s) in Company
31st May 20237:00 amRNSDirector/PDMR Shareholding
26th May 20233:17 pmRNSDirector/PDMR Shareholding
10th May 20237:00 amRNSResult of AGM
25th Apr 20237:00 amRNSBlock listing Interim Review
4th Apr 202312:36 pmRNSPosting of Annual Report and Notice of AGM
3rd Apr 20237:00 amRNSDirector/PDMR Shareholding
30th Mar 20237:00 amRNSHolding(s) in Company
28th Mar 20232:40 pmRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSFULL YEAR RESULTS FOR YEAR ENDED 31 DECEMBER 2022
16th Feb 20237:00 amRNSBlink Parametric wins new partnerships
10th Feb 20237:00 amRNSHolding(s) in Company
24th Jan 20233:56 pmRNSStatement regarding share price movement
19th Jan 20237:00 amRNSTrading Update for Financial Year 2022
20th Dec 20227:00 amRNSBlock listing Interim Review
28th Nov 20223:52 pmRNSDirector/PDMR Shareholding
16th Nov 202211:46 amRNSDirector/PDMR Shareholding
10th Nov 202211:00 amRNSBlink Parametric wins global travel sector awards
3rd Nov 20227:00 amRNSTotal Voting Rights
25th Oct 20227:00 amRNSBlock listing Interim Review
21st Oct 20227:00 amRNSDisposal of Mexican legacy business
19th Oct 20227:00 amRNSStrategy and Change Management Programme
17th Oct 20227:00 amRNSHolding(s) in Company
26th Sep 20227:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.